血浆胃泌素释放肽前体，细胞角蛋白19和癌胚抗原对各型肺肿瘤的诊断价值  

The value of plasma pro-gastrin-releasing peptide, cytokeratin 19-fragments and carcinoembryonic antigen in patients with lung cancer

作　　者：陈永健[1] 金卫东[1] 杨广宇[1] 周永列[1] 朱梅[1] 

机构地区：[1]浙江省人民医院检验中心,杭州310014

出　　处：《中华实验和临床病毒学杂志》2011年第5期381-383,共3页Chinese Journal of Experimental and Clinical Virology

基　　金：基金项目：浙江省医学重点学科基金（07-010）

摘　　要：目的探讨胃泌素释放肽前体（ProGRP），细胞角蛋白19（CYFRA21—1），癌胚抗原（CEA）对各型肺癌的诊断价值。方法检测85例健康对照人群、49例肺良性疾病患者及143例各型肺癌患者血浆中的ProGRP，CYFRA21-1，CEA三个指标，并对小细胞肺癌（SCLC）患者进行ProGRP的跟踪监测。结果SCLC患者中ProGRP水平[中位数（M）179．1ng／m1）]明显高于肺腺癌（M35．3ng／m1）、鳞癌（肘33．3ng／m1）、健康对照（膨35．6ng／m1）和良性肺病（M33．3ng／m），差异有统计学意义（P〈0．001）；ProGRP对SCLC的诊断灵敏度和特异性分别为60．6％和95．0％。SCLC治疗有效组，ProGRP降低了45．9％，SCLC疾病进展组，ProGRP升高了103．1％，差异均有统计学意义（P〈0．05）。CEA在肺腺癌转移组中水平（M10．22ng／ml）明显高于无转移组（M3．85ng／m1）和鳞癌组（M2．56ng／m1），差异有统计学意义（P〈0．01）。结论血浆ProGRP是一个很好的SCLC诊断指标和疗效评价指标；CEA明显升高是腺癌肺外转移指标。Objective To evaluate the value of plasma ProGRP,CYFRA 21-1 and CEA in patiens with lung cancer. Methods The levels of plasma ProGRP, CYFRA 21-1 and CEA were detected in 85 healthy control,49 benign lung diseases and 143 lung neoplasms. The levels of ProGRP in the patients with SCLC was monitored. Results The level of plasma ProGRP in SCLC （ M 179.1 ng/ml） was significantly higher than adenocarcinoma （ M 35.3 ng/ml） , squamous-cell carcinoma （ M 33.3 ng/ml） , healthy control （M 35.6 ng/m）and benign lung diseases（M 33.3ng/m）,P 〈 0.001. The sensitivity and specificity for diagnosing SCLC by ProGRP were 60.6% and 95.0% respectively. In the effective treatment group, ProGRP reduced 45.9% , in the progression group, ProGRP increased 103.1% , P 〈 0.05. The level of CEA in the metastatic adenocarcinoma （M 10.22 ng/ml ） was significantly higher than non-metastatic adenocarcinoma （ M 3.85ng/ml） and squamous cell carcinoma （ M 2. 56 ng/ml） （ P 〈 0. 01 ）. Conclusion The plasma ProGRP is a good indicator for diagnosing and evaluating cure effect in SCLC; the high expression of CEA is related to the metastatic adenocarcinoma.

关 键 词：肺肿瘤/诊断 癌 小细胞 胃泌素释放肽 

分 类 号：R734.2[医药卫生—肿瘤]